U.S. Chemical & Life Science Patents Q3 – 2025 Newsletter
We are pleased to share the Q3 edition of our Chemical and Life Science Patents Newsletter. Along with USPTO updates and practice tips informed by recent case law, this issue includes an explanation of the IPO’s stance against the “Skinny Labels, Big Savings Act” and guidance on PTA, PTE, and ODP. Our team provides insights into how these changes may shape innovation, IP protection, and strategic decision-making across the sector.
– USPTO Ends Accelerated Examination for Utility Patents
– USPTO Raises Track One Annual Limit
– USPTO Resumes In Person PTAB Hearings
– USPTO Unveils DesignVision AI Tool to Enhance Design Patent Searches
CASE LAW UPDATES
– Regents of the University of California v. Broad Institute, Inc., Nos. 2022‑1594, 2022‑1653 (Fed. Cir. 2025)
– Alnylam Pharms., Inc. v. Moderna, Inc., 138 F.4th 1326 (Fed. Cir. 2025)
– Eye Therapies, LLC v. Slayback Pharma, LLC, 141 F.4th 1264 (Fed. Cir. 2025)
IPO RESOLUTION
– IPO Opposes “Skinny Labels, Big Savings Act”
NEW ARTICLE
– Navigating Patent Term Adjustment And Patent Term Extension: Recent Court Rulings And Their Impact On Obviousness-Type Double Patenting
CLS PRACTICE GROUP UPDATES
– Upcoming Conferences
TO READ THE LATEST ISSUE CLICK HERE
SUBSCRIBE and get the latest insights delivered directly to your inbox!